Lisa A. Jackson, MD, MPH

“Group Health gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Lisa A. Jackson, MD, MPH

Group Health Research Institute Senior Investigator
Group Health Physician


Lisa A. Jackson is an internist and infectious disease epidemiologist who has spent the past 20 years conducting clinical and epidemiologic studies of vaccine safety and efficacy.

In addition to her role as a senior scientific investigator at Group Health Research Institute (GHRI), she is a research professor in the University of Washington (UW) Department of Epidemiology and an adjunct research professor in the UW Department of Medicine

 Dr. Jackson is the principal investigator (PI) at Group Health of the Vaccine Safety Datalink Project sponsored by the Centers for Disease Control and Prevention. She is also PI of the Vaccine and Treatment Evaluation Unit hosted by GHRI, one of eight such facilities nationwide that are sponsored by the National Institutes of Health.

Dr. Jackson has authored more than 140 peer-reviewed publications and 14 book chapters.  She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Advisory Committee.

Dr. Jackson received her medical degree from the University of Virginia School of Medicine, Charlottesville, and her master of public health degree from the University of Washington School of Public Health and Community Medicine.

Research interests and experience

  • Vaccines & Infectious Diseases

    Vaccine  safety; influenza vaccine effectiveness in the elderly; methodologic issues in  vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine  effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly;  epidemiology of E. coli bacteremia; epidemiology of community-acquired  pneumonia


Recent publications

Jackson ML, Bellamy A, Wolff M, Hill H, Jackson LA. Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adults. Epidemiol Infect. 2015 Sep 2:1-4 [Epub ahead of print]. PubMed

Jackson ML, Jackson LA, Kieke B, McClure D, Gaglani M, Murthy K, Malosh R, Monto A, Zimmerman RK, Foppa IM, Flannery B, Thompson MG. Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. Vaccine. 2015 Aug 10. pii: S0264-410X(15)01102-0. doi: 10.1016/j.vaccine.2015.07.098 [Epub ahead of print]. PubMed

Jackson ML, Peterson D, Nelson JC, Greene SK, Jacobsen SJ, Belongia EA, Baxter R, Jackson LA. Using winter 2009-2010 to assess the accuracy of methods which estimate influenza-related morbidity and mortality. Epidemiol Infect. 2015 Aug;143(11):2399-407. doi: 10.1017/S0950268814003276. Epub 2014 Dec 12.

Sukumaran L, McCarthy NL, Li R, Weintraub E, Jacobsen SJ, Hambidge SJ, Jackson LA, Naleway AL, Chan B, Tao B, Gee J. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): a comparison with the United States population. Vaccine. 2015 Jul 22. pii: S0264-410X(15)00984-6. doi: 10.1016/j.vaccine.2015.07.037. [Epub ahead of print]. PubMed


Vaccines & Infectious Diseases

Immune response to bird flu vaccine is boosted by adjuvants

Vaccine Treatment and Evaluation Unit tests real-world use to prepare for H7N9.

Read it in News and Events.

GHRI In the Media

Immune response to bird flu vaccine is boosted by adjuvants

Bird-flu vaccine needs a boost, Seattle researchers find

The Seattle Times, July 21, 2015